{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T09:16:03Z","timestamp":1778058963371,"version":"3.51.4"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007764","name":"Lanzhou Science and Technology Bureau","doi-asserted-by":"publisher","award":["2025-2-100"],"award-info":[{"award-number":["2025-2-100"]}],"id":[{"id":"10.13039\/501100007764","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007764","name":"Lanzhou Science and Technology Bureau","doi-asserted-by":"publisher","award":["2024-4-2"],"award-info":[{"award-number":["2024-4-2"]}],"id":[{"id":"10.13039\/501100007764","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007764","name":"Lanzhou Science and Technology Bureau","doi-asserted-by":"publisher","award":["2025-2-103"],"award-info":[{"award-number":["2025-2-103"]}],"id":[{"id":"10.13039\/501100007764","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012899","name":"Lanzhou University","doi-asserted-by":"publisher","award":["20250260020"],"award-info":[{"award-number":["20250260020"]}],"id":[{"id":"10.13039\/100012899","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012899","name":"Lanzhou University","doi-asserted-by":"publisher","award":["20250260016"],"award-info":[{"award-number":["20250260016"]}],"id":[{"id":"10.13039\/100012899","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012899","name":"Lanzhou University","doi-asserted-by":"publisher","award":["20250260006"],"award-info":[{"award-number":["20250260006"]}],"id":[{"id":"10.13039\/100012899","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.bcp.2026.117715","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T16:20:05Z","timestamp":1768580405000},"page":"117715","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Repurposing dronedarone for colorectal cancer therapeutic via suppression of the AKT\/ERK signaling pathways"],"prefix":"10.1016","volume":"246","author":[{"given":"Tong","family":"Gong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongmei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeying","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ning","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fanting","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingqian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.bcp.2026.117715_b0005","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"3","key":"10.1016\/j.bcp.2026.117715_b0010","first-page":"233","article-title":"Colorectal cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"issue":"19","key":"10.1016\/j.bcp.2026.117715_b0015","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.2008.20.6771","article-title":"Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial","volume":"27","author":"Andr\u00e9","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.bcp.2026.117715_b0020","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1200\/JCO.2008.20.8397","article-title":"Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer","volume":"27","author":"Bokemeyer","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"10207","key":"10.1016\/j.bcp.2026.117715_b0025","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/S0140-6736(19)32319-0","article-title":"Colorectal cancer","volume":"394","author":"Dekker","year":"2019","journal-title":"Lancet"},{"issue":"33","key":"10.1016\/j.bcp.2026.117715_b0030","doi-asserted-by":"crossref","first-page":"5080","DOI":"10.1200\/JCO.22.02773","article-title":"Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer","volume":"41","author":"de Gramont","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.bcp.2026.117715_b0035","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1200\/JCO.2004.11.069","article-title":"XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer","volume":"22","author":"Cassidy","year":"2004","journal-title":"J. Clin. Oncol."},{"issue":"13","key":"10.1016\/j.bcp.2026.117715_b0040","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1200\/JCO.2006.09.0928","volume":"25","author":"Falcone","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcp.2026.117715_b0045","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ctrv.2017.10.011","article-title":"Efficacy and safety of regorafenib in the treatment of metastatic colorectal cancer: a systematic review","volume":"62","author":"R\u00f8ed Sk\u00e5rderud","year":"2018","journal-title":"Cancer Treat. Rev."},{"issue":"15","key":"10.1016\/j.bcp.2026.117715_b0050","doi-asserted-by":"crossref","first-page":"3502","DOI":"10.1200\/JCO.2005.10.017","article-title":"Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer","volume":"23","author":"Hurwitz","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"14","key":"10.1016\/j.bcp.2026.117715_b0055","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa0805019","article-title":"Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer","volume":"360","author":"Van Cutsem","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.bcp.2026.117715_b0060","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1073\/pnas.80.8.2112","article-title":"Three human transforming genes are related to the viral ras oncogenes","volume":"80","author":"Shimizu","year":"1983","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.bcp.2026.117715_b0065","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.cell.2017.06.009","article-title":"RAS proteins and their regulators in human disease","volume":"170","author":"Simanshu","year":"2017","journal-title":"Cell"},{"issue":"13\u201314","key":"10.1016\/j.bcp.2026.117715_b0070","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.drudis.2010.05.012","article-title":"Therapeutic modulation of k-ras signaling in colorectal cancer","volume":"15","author":"Krens","year":"2010","journal-title":"Drug Discov. Today"},{"issue":"10","key":"10.1016\/j.bcp.2026.117715_b0075","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/S1470-2045(08)70206-7","article-title":"Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer","volume":"9","author":"Linardou","year":"2008","journal-title":"Lancet Oncol."},{"issue":"8","key":"10.1016\/j.bcp.2026.117715_b0080","doi-asserted-by":"crossref","first-page":"3992","DOI":"10.1158\/0008-5472.CAN-06-0191","article-title":"KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer","volume":"66","author":"Li\u00e8vre","year":"2006","journal-title":"Cancer Res."},{"issue":"15","key":"10.1016\/j.bcp.2026.117715_b0085","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1200\/JCO.2010.33.5091","article-title":"Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status","volume":"29","author":"Van Cutsem","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.bcp.2026.117715_b0090","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1158\/1078-0432.CCR-13-1610","article-title":"Molecular pathways: resistance to kinase inhibitors and implications for therapeutic strategies","volume":"20","author":"Lovly","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.bcp.2026.117715_b0095","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1080\/15384047.2019.1617568","article-title":"De novo MET amplification promotes intrinsic resistance to first-generation EGFR tyrosine kinase inhibitors","volume":"20","author":"Li","year":"2019","journal-title":"Cancer Biol. Ther."},{"issue":"4","key":"10.1016\/j.bcp.2026.117715_b0100","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1158\/1078-0432.CCR-18-1640","article-title":"Activation of KRAS mediates resistance to targeted therapy in MET Exon 14-mutant non-small cell lung cancer","volume":"25","author":"Suzawa","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.bcp.2026.117715_b0105","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"issue":"6","key":"10.1016\/j.bcp.2026.117715_b0110","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1002\/med.21446","article-title":"Artemisinin as an anticancer drug: recent advances in target profiling and mechanisms of action","volume":"37","author":"Wong","year":"2017","journal-title":"Med. Res. Rev."},{"issue":"8","key":"10.1016\/j.bcp.2026.117715_b0115","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1016\/j.apsb.2023.05.015","article-title":"Dissecting the novel abilities of aripiprazole: the generation of anti-colorectal cancer effects by targeting G\u03b1q via HTR2B","volume":"13","author":"Liu","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"issue":"6","key":"10.1016\/j.bcp.2026.117715_b0120","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/nm.3596","article-title":"Overcoming drug development bottlenecks with repurposing: repurposing biguanides to target energy metabolism for cancer treatment","volume":"20","author":"Pollak","year":"2014","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/j.bcp.2026.117715_b0125","doi-asserted-by":"crossref","first-page":"511","DOI":"10.15252\/emmm.201505421","article-title":"The anti-hypertensive drug prazosin inhibits glioblastoma growth via the PKC\u03b4-dependent inhibition of the AKT pathway","volume":"8","author":"Assad Kahn","year":"2016","journal-title":"EMBO Mol. Med."},{"issue":"1","key":"10.1016\/j.bcp.2026.117715_b0130","article-title":"Overcoming cancer therapeutic bottleneck by drug repurposing","volume":"5","author":"Zhang","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"issue":"8","key":"10.1016\/j.bcp.2026.117715_b0135","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/nrd4366","article-title":"Phenotypic screening in cancer drug discovery - past, present and future","volume":"13","author":"Moffat","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"issue":"8","key":"10.1016\/j.bcp.2026.117715_b0140","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.tips.2024.06.001","article-title":"Innovating cancer drug discovery with refined phenotypic screens","volume":"45","author":"Wang","year":"2024","journal-title":"Trends Pharmacol. Sci."},{"issue":"8","key":"10.1016\/j.bcp.2026.117715_b0145","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nrd4336","article-title":"The discovery of first-in-class drugs: origins and evolution","volume":"13","author":"Eder","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"issue":"26","key":"10.1016\/j.bcp.2026.117715_b0150","doi-asserted-by":"crossref","first-page":"10581","DOI":"10.1073\/pnas.1202810109","article-title":"Small molecule-induced cytosolic activation of protein kinase Akt rescues ischemia-elicited neuronal death","volume":"109","author":"Jo","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"2","key":"10.1016\/j.bcp.2026.117715_b0155","doi-asserted-by":"crossref","first-page":"L360","DOI":"10.1152\/ajplung.2000.279.2.L360","article-title":"Role of ras-dependent ERK activation in phorbol ester-induced endothelial cell barrier dysfunction","volume":"279","author":"Verin","year":"2000","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"issue":"35","key":"10.1016\/j.bcp.2026.117715_b0160","doi-asserted-by":"crossref","first-page":"4688","DOI":"10.1200\/JCO.2011.35.5263","article-title":"First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors","volume":"29","author":"Yap","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.bcp.2026.117715_b0165","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00210-006-0117-7","article-title":"FR180204, a novel and selective inhibitor of extracellular signal-regulated kinase, ameliorates collagen-induced arthritis in mice","volume":"374","author":"Ohori","year":"2007","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"issue":"W1","key":"10.1016\/j.bcp.2026.117715_b0170","doi-asserted-by":"crossref","first-page":"W422","DOI":"10.1093\/nar\/gkae236","article-title":"ADMETlab 3.0: an updated comprehensive online ADMET prediction platform enhanced with broader coverage, improved performance, API functionalityand decision support","volume":"52","author":"Fu","year":"2024","journal-title":"Nucl. Acids Res."},{"issue":"5","key":"10.1016\/j.bcp.2026.117715_b0175","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/0033-0620(89)90030-3","article-title":"Efficacy and toxicity of amiodarone for the treatment of supraventricular tachyarrhythmias","volume":"31","author":"Kopelman","year":"1989","journal-title":"Prog. Cardiovasc. Dis."},{"key":"10.1016\/j.bcp.2026.117715_b0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2022.116626","article-title":"Design, synthesis, and antitumor activity evaluation of novel acyl sulfonamide spirodienones","volume":"60","author":"Chen","year":"2022","journal-title":"Bioorg. Med. Chem."},{"issue":"6","key":"10.1016\/j.bcp.2026.117715_b0185","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1111\/cbdd.13043","article-title":"N-acylsulfonamides: Synthetic routes and biological potential in medicinal chemistry","volume":"90","author":"Ammazzalorso","year":"2017","journal-title":"Chem. Biol. Drug Des."},{"issue":"39","key":"10.1016\/j.bcp.2026.117715_b0190","doi-asserted-by":"crossref","first-page":"32361","DOI":"10.1039\/D5RA05157F","article-title":"Recent advances in the synthesis of N-acyl sulfonamides","volume":"15","author":"O'Driscoll","year":"2025","journal-title":"RSC Adv."},{"issue":"1","key":"10.1016\/j.bcp.2026.117715_b0195","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrm2308","article-title":"The BCL-2 protein family: opposing activities that mediate cell death","volume":"9","author":"Youle","year":"2008","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"24","key":"10.1016\/j.bcp.2026.117715_b0200","doi-asserted-by":"crossref","first-page":"7254","DOI":"10.1158\/1078-0432.CCR-07-1598","article-title":"BCL-2 family proteins: critical checkpoints of apoptotic cell death","volume":"13","author":"Danial","year":"2007","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.bcp.2026.117715_b0205","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.cell.2016.07.002","article-title":"Mitochondria and cancer","volume":"166","author":"Vyas","year":"2016","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.bcp.2026.117715_b0210","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.cmet.2020.06.019","article-title":"Mitochondrial metabolism as a target for cancer therapy","volume":"32","author":"Vasan","year":"2020","journal-title":"Cell Metab."},{"issue":"3","key":"10.1016\/j.bcp.2026.117715_b0215","article-title":"Intracellular and microenvironmental regulation of mitochondrial membrane potential in cancer cells","volume":"15","author":"Begum","year":"2023","journal-title":"WIREs Mech. Dis."},{"issue":"21","key":"10.1016\/j.bcp.2026.117715_b0220","doi-asserted-by":"crossref","first-page":"9861","DOI":"10.1158\/0008-5472.CAN-05-2444","article-title":"The intrinsic mitochondrial membrane potential of colonic carcinoma cells is linked to the probability of tumor progression","volume":"65","author":"Heerdt","year":"2005","journal-title":"Cancer Res."},{"issue":"19","key":"10.1016\/j.bcp.2026.117715_b0225","first-page":"6311","article-title":"The intrinsic mitochondrial membrane potential (Deltapsim) is associated with steady-state mitochondrial activity and the extent to which colonic epithelial cells undergo butyrate-mediated growth arrest and apoptosis","volume":"63","author":"Heerdt","year":"2003","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.bcp.2026.117715_b0230","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ccr.2006.10.020","article-title":"A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth","volume":"11","author":"Bonnet","year":"2007","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bcp.2026.117715_b0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102943","article-title":"Cancer metabolism and mitochondria: finding novel mechanisms to fight tumours","volume":"59","author":"Missiroli","year":"2020","journal-title":"EBioMedicine"},{"issue":"1","key":"10.1016\/j.bcp.2026.117715_b0240","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.canlet.2015.06.024","article-title":"Colorectal cancer-derived tumor spheroids retain the characteristics of original tumors","volume":"367","author":"Lee","year":"2015","journal-title":"Cancer Lett."},{"issue":"7","key":"10.1016\/j.bcp.2026.117715_b0245","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/j.cell.2007.06.009","article-title":"AKT\/PKB signaling: navigating downstream","volume":"129","author":"Manning","year":"2007","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.bcp.2026.117715_b0250","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.cell.2010.06.011","article-title":"Cell signaling by receptor tyrosine kinases","volume":"141","author":"Lemmon","year":"2010","journal-title":"Cell"},{"issue":"6141","key":"10.1016\/j.bcp.2026.117715_b0255","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1126\/science.1233606","article-title":"Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay","volume":"341","author":"Martinez Molina","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.bcp.2026.117715_b0260","first-page":"27","article-title":"Dronedarone: current evidence for its safety and efficacy in the management of atrial fibrillation","volume":"5","author":"Schweizer","year":"2011","journal-title":"Drug Des. Devel. Ther."},{"issue":"9","key":"10.1016\/j.bcp.2026.117715_b0265","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1592\/phco.30.9.904","article-title":"Dronedarone: a new antiarrhythmic agent","volume":"30","author":"Oyetayo","year":"2010","journal-title":"Pharmacotherapy"},{"issue":"4","key":"10.1016\/j.bcp.2026.117715_b0270","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1161\/CIRCEP.111.963447","article-title":"Acute liver failure associated with dronedarone","volume":"4","author":"Joghetaei","year":"2011","journal-title":"Circ. Arrhythm. Electrophysiol."},{"issue":"7","key":"10.1016\/j.bcp.2026.117715_b0275","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1001\/jama.2021.0106","article-title":"Diagnosis and treatment of metastatic colorectal cancer: a review","volume":"325","author":"Biller","year":"2021","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.bcp.2026.117715_b0280","first-page":"308","article-title":"Cancer treatment and survivorship statistics, 2025","volume":"75","author":"Wagle","year":"2025","journal-title":"CA Cancer J. Clin."},{"issue":"9423","key":"10.1016\/j.bcp.2026.117715_b0285","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1016\/S0140-6736(04)16308-3","article-title":"Thalidomide","volume":"363","author":"Franks","year":"2004","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.bcp.2026.117715_b0290","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.2165\/00003495-200464110-00004","article-title":"Zoledronic acid: a review of its use in patients with advanced cancer","volume":"64","author":"Perry","year":"2004","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.bcp.2026.117715_b0295","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nrendo.2013.256","article-title":"Metformin\u2013mode of action and clinical implications for diabetes and cancer","volume":"10","author":"Pernicova","year":"2014","journal-title":"Nat. Rev. Endocrinol."},{"issue":"1","key":"10.1016\/j.bcp.2026.117715_b0300","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13046-023-02671-8","article-title":"Irbesartan overcomes gemcitabine resistance in pancreatic cancer by suppressing stemness and iron metabolism via inhibition of the Hippo\/YAP1\/c-Jun axis","volume":"42","author":"Zhou","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.bcp.2026.117715_b0305","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1001\/jamaoncol.2020.7338","article-title":"Aspirin use and risk of colorectal cancer among older adults","volume":"7","author":"Guo","year":"2021","journal-title":"JAMA Oncol."},{"issue":"10","key":"10.1016\/j.bcp.2026.117715_b0310","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1158\/1940-6207.CAPR-19-0006","article-title":"A Randomized phase II trial of pioglitazone for lung cancer chemoprevention in high-risk current and former smokers","volume":"12","author":"Keith","year":"2019","journal-title":"Cancer Prev. Res. (Phila.)"},{"key":"10.1016\/j.bcp.2026.117715_b0315","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.pharmthera.2017.10.018","article-title":"Emerging tumor spheroids technologies for 3D in vitro cancer modeling","volume":"184","author":"Rodrigues","year":"2018","journal-title":"Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.bcp.2026.117715_b0320","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s43556-022-00110-2","article-title":"Targeting the PI3K\/AKT\/mTOR and RAF\/MEK\/ERK pathways for cancer therapy","volume":"3","author":"Li","year":"2022","journal-title":"Mol. Biomed."},{"issue":"4","key":"10.1016\/j.bcp.2026.117715_b0325","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/leu.2008.26","article-title":"Contributions of the Raf\/MEK\/ERK, PI3K\/PTEN\/Akt\/mTOR and Jak\/STAT pathways to leukemia","volume":"22","author":"Steelman","year":"2008","journal-title":"Leukemia"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226000468?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226000468?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T08:35:01Z","timestamp":1778056501000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295226000468"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":65,"alternative-id":["S0006295226000468"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2026.117715","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Repurposing dronedarone for colorectal cancer therapeutic via suppression of the AKT\/ERK signaling pathways","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2026.117715","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117715"}}